Funding for the development of this Practice Guidance was provided by the American
Association for the Study of Liver Diseases. MV was supported by aAQ19 Patient-Centered …

PURPOSE: The financial toxicity of anticancer drugs is well-documented, but little is known
about the costs of drugs used to manage cancer-associated symptoms. METHODS: We …

The unfavorable risk: benefit ratio of high-dose dexamethasone suggests that it should not
be routinely prescribed for dyspnea in cancer patients. More research is needed to assess …

Background Systemic corticosteroids are commonly prescribed for palliation of dyspnoea in
patients with cancer, despite scarce evidence to support their use. We aimed to assess the …

Background: Severe and refractory chronic breathlessness is a common and burdensome
symptom in patients with advanced life-limiting disease. Its clinical management is …

Should opioids be used for breathlessness and in whom? A PRO... : Current Opinion in
Supportive and Palliative Care Should opioids be used for breathlessness and in whom? A …

In the older adult with a serious illness, the goal of palliative medicine, especially when
focusing on symptom management, is to optimize quality of life. As we discuss pain …

PURPOSE In patients with lung cancer, dyspnea is one of the most prevalent and disabling
symptoms, for which effective treatments are lacking. We examined the efficacy of a nurse …

Malignant pleural effusion (MPE) has become an increasingly prevalent complication in
oncological patients, negatively impacting their quality of life and casting a shadow over …

Globally, engagement of patients in the self management of disease and symptom problems
has become a health policy priority to improve health outcomes in cancer. Unfortunately …